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weeks), while those with unchanged or increased levels were between 1-3 weeks (mean: 
2.0 ± 0.6 weeks, p = 0.06) following LVAD treatment. TIMP-1 and TIMP-4 transcript lev- 
els increased in 4 and decreased in 3 patients. Changes in gene expression of those two 
transcripts correlated positively with each other during LVAD support (r2: 0.9, p < 0.001). 
There was no correlation between TIMP expression and time on support, and there was 
no reciprocal change in MMP expression. 
Conclusions: Myocardial gene expression of MMP-I., MMP-9, TIMP-1, and TIMP-4 do 
not change predictably during LVAD treatment, with the exception of MMP-9, which 
decreased after 3 weeks. These findings suggest a non-linear or biphasic response of 
MMP-9 expression with mechanical unloading. In addition, the positive correlation 
between changes in transcript levels of TIMP 1 and 4 suggest a common transcdptional 
mechanism. 
4:30 p.m. 
876-3 Expression Profiling of Genes in Eight Failing and 
Seven Nonfailing Human Hearts by Oligonucleotide 
Microarrays 
Fen-Lai Tan. Christine S. Moravec, Jianbo Li, Carolyn Apperson-Hansen, Patrick M. 
McCarthy, James B. Young, Meredith Bond, The Cleveland Clinic Foundation, Cleveland, 
Ohio. 
Background: Systematic expression profiling of genes at the global level in multiple 
human hearts in order to generate a complete complement of heart failure genes, has 
not been reported to date. 
Methods: Using oligonucleotide microarrays (Hu-6800, Affymetrix. Inc, CA), complemen- 
tary RNA isolated from left ventricular free wall of 7 non-failing (NF) and 8 failing human 
(FH) hearts (diagnosis: idiopathic dilated cardiomyopathy) was profiled for gene expres- 
sion. Using WUcoxon Rank-Sum test (P<0.05) and Student's T-test after log-transforma- 
tion (P<0.05), 1145 out of -7000 genes on the chip that are potentially differentially 
expressed between NF and FH hearts was generated. After elimination of genes with 
<1.5 fold change in expression level, 387 remained significant. To minimize the likelihood 
of false positives, a minimum mean average difference of 200 units was imposed. Of the 
387 genes, this additional cut-off point generated 115 genes with increased expression 
and 74 genes with decreased expression in the FH hearts. This comprehensive cut-off 
point is being confirmed by quantitative PCR. 
Results: 189 genes in 10 clusters were found differentially expressed between the NF 
and FH heads. As validation of this approach, changes in expression of a number of 
these genes are well documented, e.g. biomarkers for heart failure (ANF, BNP, troponin 
T1) were significantly increased, and several contractile proteins (e.g. a cardiac actin, 
myosin light chain) were significantly decreased. However, the majority of the genes 
have not previously been reported, e.g. up-regulated human brahma-related gene-1 
(BRG1, the ATPase subunit of SWI/SNF, involved in MyoD-mediated muscle differentia- 
tion) and thrombospondin-4 (an extracellullar Ca2+-binding adhesion protein, associated 
with increased dsk of early heart attack); down-regulated metallothionein (an inhibitor of 
the MAP kinase pathway, involved in resistance of Doxorubicin cardiotoxicity) and anti- 
chymotrypsin (a proteinase inhibitor, reported to attenuate myocardial ischemic injury). 
Conclusions: Novel findings include changes in expression of genes with a potential role 
in cardiac remodeling. 
4:45 p.m. 
876-4 Microarray Analysis of Changes in Gene Expression 
Following LVAD Support 
Nicholas R. DiPaola, Nicholas G. Smedira, Patrick M. McCarthy, James B. Young, 
Christine S. Moravec, Cleveland Clinic Foundation, Cleveland, Ohio. 
Data from our laboratory and others suggest that mechanically unloading the failing 
human head with a left ventricular assist device (LVAD) results in improved muscle func- 
tion and altered gene expression. Although provocative, such studies fail to address the 
interaction between genes or the possibility that groups of genes are coordinately regu- 
lated. We studied paired tissue samples from four patients before and after LVAD, using 
the Affymetdx Microarray system to simultaneously measure expression of 7000 genes. 
Patients were male, between 35 and 55 years of age, and had dilated cardiomyopathy. 
Duration of LVAD support was short (35 days) in two patients, and long (135 days) in two 
patients. Total RNA was prepared from tissue removed during LVAD implant and at trans- 
plant in all patients. RNA samples were reverse transcribed and in vitro translated into 
biotinylated cRNA, which was hybridized to Affymetdx human gene chip arrays. Analysis 
revealed the presence of 3476 genes, of which 196 were changed following LVAD sup- 
port in at least three of the patients (69 genes), or were differentially regulated by dura- 
tion of support (97 genes). Significant changes in gene expression in all four patients 
following mechanical unloading included a 4.5 fold decrease in atrial natriuratic factor 
and a 5.3 fold decrease in phosphotipase A2, as well as an 11.0 fold increase in in c-fos, 
a 4.3 fold increase in plasminogen activator inhibitor-t, a 3.4 fold increase in a zinc finger 
transcriptional repressor of TNF, and a 2.7 fold increase in protein tyrosine phosphatase. 
Genes which were differentially regulated based on duration included a 2.6 fold increase 
in GATA-4 in short duration patients, with no change following long duration support, as 
well as no change in protein phosphatase 2A during short term support, but a 2.0 fold 
increase following longer durations. Although much data remains to be analyzed, and the 
functional significance of these changes remains to be explored, the analysis of paired 
samples from LVAD-supported patients using Microarray techniques is a powerful 
approach for elucidating the coordinate changes in gene regulation following hemody- 
namic unloading of the failing human heart. 
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4:00 p.m. 
879-1 Reverul of Cardiogenic Shock by Left Atrial-to-Femoral 
Arterial Bypass Assistance 
Holoer Thiele. Bemward Lauer, Enno Bouddot, Angela Genov, Rainer Hambrecht, 
Gerhard Schuler, University of Leipzig - Heart Center, Leipzig, Germany. 
Background: Mortality in cardiogenic shock following acute myocardial infarction remains 
at an unacceptable level despite interventional treatment of the underlying cause and 
use of intraaortic balloon counterpulsation. Frequently patients succumb to low cardiac 
output before the myocardium is able to recover from the ischemic event, A newly devel- 
oped left ventricular assist device (Tandem Heart pVAD, Cardiac Assist Technologies, 
Inc., Pittsburgh, Pennsylvania, USA) with active circulatory support might decrease mor- 
tality. 
Methods and results: Between 05/2000 and 0912001 in 19 consecutive patients with car- 
diogenic shook a percutaneous left atdat-to-femoral rterial bypass assist device was 
implanted. The device was connected to the patients' circulation by transseptal puncture 
of the left atdum; blood was returned to the lilac artery through an artedal cannula. In 13 
patients cardiogenic shook was caused by an acute myocardial infarction and in 6 by an 
infarct related ventricular septal defect. Mean duration of cardiac assist was 4±3 days. 
Mean flow of the device was 3.3±0.6 I/min. Before support cardiac index was 1.7±0.3 I/ 
min/qm and improved to 2,4±0.6 I/min/qm (p<0.001) with cardiac assist, Mean blood 
pressure increased from 64±8 mmHg to 80±9 mmHg (p<0,001). Pulmonary capillary 
wedge pressure, central venous pressure and mean pulmonary artery pressure were 
reduced from 20¢5, 12¢4 and 31±8 mmHg to 14±4, 9±3 and 23±6 mmHg (all p<0.01), 
respectively. Overall mortality was 42%. 
Conclusion: In patients with cardiogenic shock hemedynamic parameter can be substan- 
tially enhanced by use of a percutaneous left atdal-to-famoral arterial assist device, It 
provides up to 4.0 I/rain Of additional cardiac output, which is sufficient o revert cardio- 
genic shock in most patients. By diverting blood from the left atrium the left ventricular 
myocardium is unloaded, making recovery more likely following an ischemic event. The 
influence of this device on long-term prognosis warrants further investigations. 
4:15 p.m. 
879-2 The Paraaortic Counterpulsat ion Device Implanted on 
the Ascending Aorta Is Superior to an Equal Volume 
Intraaortic Bal loon Pump: Experimental Study 
John Terrevitis. Chdstos Charitos, Paraskevi Dolou, Argyrios Ntalianis, Stavros Drakos, 
Charalampos Pierakos, Kostas Chalkias, Panagiotis Papazoglou, John Nanas, 
Department of Clinical Therapeutics, University of Athens, Athens, Greece. 
Backround:We aimed to compare the hemodynamic effects of a 40ml total volume 
paraaodic counterpulsation device (PACD, stroke volume 30ml) to those of a 40ml 
intraaortic balloon pump (IABP), in an acute experimental porcine model of heart failure. 
Methods: In 6 pigs, weighting 53 to 64kgr, left ventdcular failure was induced with multi- 
ple ligations of small coronary arteries and propranolol and amiodarene infusion. The 
IABP was placed into the descending aorta and the PACD was implanted in the ascend- 
ing aorta via a 3cm vascular graft. Aortic pressures were recorded with and without 
mechanical assistance, provided by the IABP and the PACD, alternately. Cardiac output 
was monitored using a transit time ultrasound flowmetar placed on the pulmonary artery, 
Double Product (DP), Tension Time Index (l-rl), Diastolic Pressure Time Index (DPTI) 
and Endocardial Viability Ratio (EVR) were calculated. Both devices were driven by the 
Datascope 96 driving system. 
Results: The hemodynamic effectiveness of the devices was evaluated from their ability 
to reduce the aftedoed of the left ventricle and to provide diastolic aortic augmentation. 
Both significantly reduced the systolic aortic pressure (from 112 ± 18mmHg to 100 ± 17, 
p=0.000, and to 98 ± 23, p=0,000, using the IABP and the PACD, respectively) and the 
end diastolic aortic pressure, (from 82 ± 17mmHg to 74 ± 19, p=0.000 and to 50 ± 22, 
p=O.000, respectively). The PACD reduced the end diastolic aortic pressure more than 
the IABP (reduction of 42.6 ± 18.1% vs 11.0 ± 9.9%, p=0.000). The counterpulsation 
wave of the PACD was significantly greater than that of the IABP (augmentation of 44.8 ± 
22,2% vs 37.6 ± 15.6%, p=0.031). Both devices significantly lowered the end diastolic left 
ventricular pressure, DP and TTI and increased cardiac output, DPTI and EVR compara- 
bly, 
Conclusion: Both devices showed significant hemodynamic effects in left ventdcular 
function. Although the PACD was of a smaller stroke volume, it provided greater salutary 
hemodynamic effects. The simplicity of the implantation procedure of the PACD and the 
ability to be driven by the standard IABP driving system make it a promising device for 
wide use for mechanical assistance of the failing heart. 
